MarwanGFakihMD

Oncology • Duarte, CA

Gastrointestinal Cancer, Hematologic Oncology

Professor Section Head, Gastrointestinal Oncology Medical Director, Briskin Center for Clinical Research

Join to view full profile

Dr. Fakih is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fakih's full profile

Already have an account?

Office
Medical Oncology and Therapeutics Research
1500 East Duarte Road
Duarte, CA 91010
Phone+1 626-256-4673

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 1998 - 2001
Wayne State University School of MedicineResidency, Internal Medicine, 1992 - 1995
American University of Beirut Faculty of MedicineClass of 1992

Certifications & Licensure

CA State Medical License 2012 - 2025
MI State Medical License 1994 - 2015
NY State Medical License 2002 - 2011
PA State Medical License 1997 - 2002
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation Start of enrollment: 2023 Jul 27
Recruiting
Phase 1
Roles: Contact
Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors Start of enrollment: 2021 Apr 11
Recruiting
Phase 1, Phase 2
Roles: Contact
Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy Start of enrollment: 2023 May 11
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation Start of enrollment: 2024 Feb 05
Recruiting
Phase 1
Roles: Principal Investigator, Contact
GCC19CART for Patients With Metastatic Colorectal Cancer Start of enrollment: 2022 Aug 01
Recruiting
Phase 1
Roles: Contact
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors Start of enrollment: 2023 Feb 15
Recruiting
Phase 1
Roles: Principal Investigator, Contact
FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer Start of enrollment: 2023 May 03
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Sex and outcomes of patients with microsatellite instability-high andV600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors.
Vincenzo Nasca, Joseph Zhao, Javier Ros, Sara Lonardi, Koen Zwart
Journal for Immunotherapy of Cancer. 2025-02-10
ASO Visual Abstract: Impact of PIPAC-Oxaliplatin on Functional Recovery, Good Days, and Survival in Refractory Colorectal and Appendiceal Carcinomatosis-Secondary Anal...
Muhammad Talha Waheed, Nora Ruel, Richard L Whelan, Marwan Fakih, Yuman Fong
Annals of Surgical Oncology. 2025-02-01
An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study.
Caiming Xu, Alessandro Mannucci, Francis Esposito, Helena Oliveres, Vicente Alonso Orduña
Clinical Cancer Research. 2025-01-17

Press Mentions

The Mystery of What’s Causing Young People’s Cancer Leads to the GutJanuary 3rd, 2025
More Younger People Are Getting Colonoscopies, a New Study SuggestsOctober 3rd, 2024
Surge in Colon Cancer: What Gen X, Millennials and Gen Zer’s Need to KnowMarch 6th, 2024